Olga Bodriagova
Research Subjects
Olga Bodriagova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Kamal S. Saini
Fortrea Inc., Durham, USA
2 shared publications - Laura Vidal
Fortrea Inc., Durham, USA
2 shared publications - Abhishek Shankar
Department of Radiation Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi, India
1 shared publication - Arun K. Mankan
Fortrea Inc, Durham, NC
1 shared publication - Begona de Las Heras
Fortrea Inc., Durham, USA
1 shared publication - Enrique Grande
Department of Medical Oncology, Quironsalud Madrid, Pozuelo de Alarcón, Spain
1 shared publication
Latest Publications
- 10 January 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (3) , 885-890
Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy
Immune checkpoint inhibitors (ICI) have emerged as an important therapeutic approach for patients with cancers including bladder cancer (BC). This commentary describes a recent study that demonstrated that the loss of Y chromosome (LOY) and/or loss of specific genes on Y chromosome confers an aggressive phenotype to BC because of T cell dysfunction resulting in CD8+T cell exhaustion. Loss of expression of Y chromosome genes KDM5D and UTY was similarly associated with an unfavorable prognosis in patients with BC as these genes were partially responsible for the impaired anti-tumor immunity in LOY tumors. From a clinical perspective, the study showed that tumors with LOY may be susceptible to treatment with ICIs.
- 10 January 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (3) , 885-890
Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy
Immune checkpoint inhibitors (ICI) have emerged as an important therapeutic approach for patients with cancers including bladder cancer (BC). This commentary describes a recent study that demonstrated that the loss of Y chromosome (LOY) and/or loss of specific genes on Y chromosome confers an aggressive phenotype to BC because of T cell dysfunction resulting in CD8+T cell exhaustion. Loss of expression of Y chromosome genes KDM5D and UTY was similarly associated with an unfavorable prognosis in patients with BC as these genes were partially responsible for the impaired anti-tumor immunity in LOY tumors. From a clinical perspective, the study showed that tumors with LOY may be susceptible to treatment with ICIs.
- Open Access
- 15 September 2023
- Published by Springer Nature in Oncology and Therapy
- Vol. 11 (4) , 397-409
Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
- 15 September 2023
- Published by Springer Nature in Oncology and Therapy
- Vol. 11 (4) , 397-409
Open AccessRecent Advances in Gynecological Malignancies: Focus on ASCO 2023